Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232600 | 0.79 | OPRD1 (0.44) | GPR119OPRD1OPRK1JAK2JAK1 | |
| SCHEMBL29247221 | 0.79 | OPRD1 (0.43) | TACR1GPR119OPRD1OPRK1JAK2 | |
| SCHEMBL5225612 | 0.77 | OPRD1 (0.42) | GPR119OPRD1OPRK1JAK2JAK1 | |
| SCHEMBL1049597 | 0.77 | OPRD1 (0.49) | TACR1GPR119OPRD1OPRK1JAK2 | |
| SCHEMBL19124768 | 0.76 | OPRD1 (0.46) | GPR119OPRD1OPRK1JAK2JAK1 | |
| SCHEMBL19124519 | 0.76 | MEN1 (0.44) | GPR119OPRD1OPRK1MEN1KMT2A | |
| SCHEMBL17467896 | 0.75 | OPRD1 (0.45) | GPR119OPRD1OPRK1JAK2JAK1 | |
| SCHEMBL20722852 | 0.74 | OPRD1 (0.45) | GPR119OPRD1OPRK1JAK2JAK1 | |
| SCHEMBL28607334 | 0.73 | OPRD1 (0.43) | TACR1GPR119OPRD1OPRK1JAK2 | |
| SCHEMBL21731415 | 0.73 | OPRD1 (0.44) | GPR119OPRD1OPRK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060473-A1 | Piperazine compounds as inhibitors of MMP or TNF | MMP2, MMP1, TNF | TACR1 989/4885GPR119 2709/4885OPRD1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.